Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

NZ sharemarket declined almost 2% this week
Markets Market close

NZ sharemarket declined almost 2% this week

The S&P/NZX 50 Index closed at 12,809.59 points, down 87.36 points or 0.68%.

Graham Skellern 06 Dec 2024
Updated: Methanex paid $200m to idle operations
Markets

Updated: Methanex paid $200m to idle operations

Genesis and Contact forked out millions to keep the lights on.

Ian Llewellyn 06 Dec 2024
THL slashes about 100 jobs
Markets

THL slashes about 100 jobs

THL is targeting a $12m after-tax profit cost savings in the 2027 financial year.

John Anthony 06 Dec 2024
Fonterra comfortable with co-op's margins
Primary Sector

Fonterra comfortable with co-op's margins

An extra $500 million is set to be paid out to its farmers from January.

Riley Kennedy 06 Dec 2024